Geneva, 10 December 2021 – Gavi, the Vaccine Alliance announced today that it reached an agreement to access an additional 150 million doses of the mRNA vaccine against COVID-19 manufactured by Moderna, to be made available to COVAX at their lowest global tiered price. This amendment to the existing advance purchase agreement (APA) between Gavi and Moderna means a total of up to 650 million doses of the Moderna vaccine could be available to COVAX participants through 2021 and 2022.
As part of an urgent call for manufacturers to prioritise supply to COVAX, Gavi and Moderna have also reached agreement to pre-pone the availability of 20 million doses to COVAX. These doses, originally scheduled to be released to COVAX in Q1 2022, are now being made available in Q4 2021 instead.
“We are very pleased to announce this agreement with Moderna for additional volumes and earlier access to doses for COVAX participants,” said Aurélia Nguyen, Managing Director of the Office of the COVAX Facility. “We continue to actively manage the COVAX portfolio to respond to the needs of countries and remain adaptable in the face of this continually evolving pandemic: this agreement is a further step in that direction. Gavi encourages all manufacturers to continue to prioritize transparent, consistent, and predictable supply to COVAX – providing lower-income countries with the long-term visibility required to plan successful vaccination campaigns and increase coverage rates.”
As part of the largest and most complex vaccine rollout in history, COVAX has so far delivered more than 650 million doses to 144 countries. Despite initial supply setbacks, deliveries continue to accelerate steadily and will continue to do so through the end of the year and into 2022. As COVAX works closely with low- and lower-middle-income countries to support readiness and increase absorptive capacity, predictable supply, along with tailored delivery funding and support, will be critical to ensuring these countries can plan ahead for successful rollout – and thus achieve higher coverage rates.